Healthcare Business - Page 2

Even More Biopharma and FDA Catalysts Coming in October

As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector ...
Read Full Story »

4 Biotech Stocks to Buy That May See Huge Volatility From Earnings

With the third-quarter earnings reporting season upon us, investors are checking their holdings and research to see just how things are shaping up for stocks they own. One thing is ...
Read Full Story »

Why ImmunoGen’s Secondary Makes Sense

ImmunoGen Inc. (NASDAQ: IMGN) saw its shares make a sharp turn downward early Thursday morning after the stock has seen an incredible year of trading so far. Shares taking a ...
Read Full Story »

What CytomX Gets From Its Huge Amgen Collaboration

CytomX Therapeutics Inc. (NASDAQ: CTMX) shares saw a solid gain in Wednesday’s session following announcement of a strategic collaboration with Amgen Inc. (NASDAQ: AMGN) in immuno-oncology. The companies are planning ...
Read Full Story »

Amicus Therapeutics Wins Big at World Muscle Society Conference

Amicus Therapeutics Inc. (NASDAQ: FOLD) is another biotech player that’s seeing a nice boost from the World Muscle Society Conference in France. In this case, the company announced additional positive ...
Read Full Story »

Why Catabasis Shares Are Surging

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) shares continued their incredible climb after the firm announced positive efficacy results from its MoveDMD trial in Duchenne muscular dystrophy (DMD). These results were presented ...
Read Full Story »

Is This the Turnaround That Mylan Has Waited For?

Finally some good news out of Mylan N.V. (NASDAQ: MYL), which is potentially bringing the shares back to about even for 2017. The pharmaceutical firm announced that the U.S. Food ...
Read Full Story »

Credit Suisse Identifies Top Mid-Large Cap Biotech and Pharma Stocks for Big Upside

U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. The firm is looking at pharma and biotech opportunities around politics, drug pipelines and ...
Read Full Story »

Why Morgan Stanley Sees Over 30% Upside in Sarepta

Shares of Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s ...
Read Full Story »

Why Endocyte Is Monday’s Biggest Winner

Endocyte Inc. (NASDAQ: ECYT) kicked off the week with an incredible gain, making it one of the best, if not the best, performing stocks in Monday’s session. This massive gain ...
Read Full Story »

FDA Update Keeps Rigel Pharmaceuticals Above Water

Shares of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) saw a solid gain to start off the week after the company gave an update from its meeting with the U.S. Food and ...
Read Full Story »

Major Biotech, Pharma and FDA Catalysts Coming in October

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »

Why Zogenix Shares More Than Doubled

Zogenix Inc. (NASDAQ: ZGNX) saw its shares more than double early on Friday after the company reported positive top-line results from its most recent late-stage trial in the treatment of ...
Read Full Story »

AbbVie and Amgen Reach Global Resolution of Humira

AbbVie Inc. (NYSE: ABBV) shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen Inc. (NASDAQ: AMGN). What’s important ...
Read Full Story »

Zynerba Pharma Wins Big on Cannabis Trial

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial. Specifically, the firm was evaluating ZYN002 ...
Read Full Story »